<?xml version="1.0" encoding="UTF-8"?>
<ref id="B42-vaccines-08-00174">
 <label>42.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kirstein</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Douglas</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Thakur</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Boaz</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Papa</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Skipetrova</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Plennevaux</surname>
    <given-names>E.</given-names>
   </name>
  </person-group>
  <article-title>Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: Randomised phase II study in US adults</article-title>
  <source>BMC Infect. Dis.</source>
  <year>2018</year>
  <volume>18</volume>
  <elocation-id>475</elocation-id>
  <pub-id pub-id-type="doi">10.1186/s12879-018-3389-x</pub-id>
  <?supplied-pmid 30241510?>
  <pub-id pub-id-type="pmid">30241510</pub-id>
 </element-citation>
</ref>
